16/04/2018 16:30:30

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself

Related content
18 Apr - 
FIT Biotech Oy: Conversion of FIT Biotech Oy's Converti..
12 Apr - 
FIT Biotech Oy: Resolutions of the Annual General Meeti..
29 Mar - 
CORRECTION: FIT Biotech Oy: FIT Biotech Oy's Board of D..

FIT Biotech Oy

Company release April 16, 2018 at 6:30 pm EET

FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself

FIT Biotech Oy's Board of Directors has resolved to issue 1,000,000,000 new K shares without payment to the Company itself based on the authorization granted by the General Meeting on April 12, 2018.

The total authorization was 2,000,000,000 K shares. There are authorizations for 1,000,000,000 K-shares to issue shares to the Company itself left after this issuance.

The purpose is to use the shares to implement convertible loan note and share warrant funding programmes.

FIT BIOTECH OY

Board of Directors

For further information:

CEO Erkki Pekkarinen

Tel: +358 44 027 0080

E-mail: erkki.pekkarinen@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech

FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:

NASDAQ OMX Helsinki

Principal media


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: FIT Biotech Oy via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
2
Leading Petroleum Industry Engineer and Researcher Joins Stamper Oil and Gas Technical Advisory Board
3
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
4
Brookfield Residential’s Stunning New Agave Neighborhood to Debut Soon at Spencer’s Crossing in Murrieta
5
Urban Airship Names Michael Stone as Senior Vice President of Marketing

Related stock quotes

FIT Biotech Oy 0.0012 -14.3% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 April 2018 05:47:29
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180417.1 - EUROWEB1 - 2018-04-20 06:47:29 - 2018-04-20 05:47:29 - 1000 - Website: OKAY